权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Frontiers in HIV Pathogenesis, Therapy and Eradication

HIV发病机制、治疗和根除的前沿

基本信息

批准号：
8260640
负责人：
James Wavell Aiken
金额：
$ 2万
依托单位：
KEYSTONE SYMPOSIA
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-01-09 至 2012-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8260640
关键词：
AIDS/HIV problem Academia Acquired Immunodeficiency Syndrome Address Antiviral Therapy Area Arts Biology Biology of HIV Infection British Columbia Canada Cells Cellular biology Cessation of life Chronic Hepatitis Collaborations Communication Communication Research Drug Formulations Drug resistance Educational workshop Environment Exposure to Fostering Gene Expression HIV HIV-1 Highly Active Antiretroviral Therapy Industry International Joints Knowledge Maintenance Mentors Methodology Outcome Pathogenesis Patients Pharmacology Private Sector Request for Applications Research Research Personnel Science Scientist Study models Training Viral Viral hepatitis Virus abstracting clinical practice drug development experience frontier inhibitor/antagonist interest latent infection meetings novel pandemic disease resistant strain symposium virus host interaction

项目摘要

DESCRIPTION: This application requests support for a Keystone Symposia meeting entitled Frontiers in HIV Pathogenesis, Therapy and Eradication, organized by Alan N. Engelman, Eric O. Freed and John M. Coffin, which will be held in Whistler, British Columbia, Canada from March 26-31, 2012. AIDS is incurable because cells latently infected with HIV resist antiviral therapy. Topical to the discussion of HIV eradication is the biology behind latent infection as well as models for the study of latency and pharmacological approaches to stimulate proviral gene expression. The Keystone Symposia meeting on Frontiers in HIV Pathogenesis, Therapy and Eradication will create an environment for free exchange of ideas and cutting edge results from a range of scientists in academia and industry in the fields of HIV pathogenesis, pharmacology, and eradication. Joint plenary sessions with the concurrent meeting on Cell Biology of Virus Entry, Replication and Pathogenesis will highlight common topics of interest including mechanisms of virus entry and inhibition, and will significantly enhance opportunities for interdisciplinary interactions. Leaders from HIV replication and drug resistance fields will critically examine the state of antiviral therapy, novel inhibitors, and important virus-host interactions. Speakers selected from submitted abstracts will fill-out workshops on pharmacological approaches and the cell biology of HIV infection. PUBLIC HEALTH RELEVANCE: The 2012 Keystone Symposium on Frontiers in HIV Pathogenesis, Therapy and Eradication will address key issues related to the control of the global HIV/AIDS pandemic including potential eradication of persistent viral reservoir(s) from patients. Considering that UNAIDS estimated 1.8 million AIDS-related deaths in 2009, the meeting is both timely and highly significant. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Cell Biology of Virus Entry, Replication and Pathogenesis, which will share a keynote address and two plenary sessions with this meeting.

描述: